Skip to main content

Table 2 Demographic and clinical data of 22 patients with autoimmune rheumatic disease (AIRD) and positive cytomegalovirus antigenemia

From: Incidence of Cytomegalovirus Antigenemia in patients with autoimmune rheumatic diseases: a 3-year retrospective study

Female sex

19 (90%)

Age (years)a

39.4 ± 20.8

AIRD

 SLE

13 (59%)

 ANCA-associated Vasculitis

4 (18.2%)

 RA

2 (9%)

 Systemic sclerosis

1 (4.5%)

 Overlap syndrome

1 (4.5%)

 Anti-sintetase syndrome

1 (4.5%)

Diagnosis AIRDb Time (months)

10.5 (0–276)

Hospitalization causea

 Activity + Infection

11 (50%)

 Infection only

8 (36.5%)

 Activity only

3 (13.6%)

AIRD treatment

Maximum dose of corticosteroids in hospital (mg/ day)a

87.7 ± 52.5

 Corticosteroids dose above 1 mg /kg/ daya

19 (86.4%)

 Methylprednisolone Pulse Therapya

11 (50%)

Immunosuppressant medicationsa

11 (50%)

Site of CMV infectiona

 Lung

10 (45.4%)

 Cytopenia

9 (40.9%)

 Gastrointestinal tract

6 (27.3%)

Hospitalization timea(days)

41.9 ± 34.1

Hospitalization time until CMV-Ag be requesteda(days)

11.5 ± 12

Time of symptoms until CMV-Ag be requesteda(days)

7.8 ± 7.1

Time from the first positive CMV-Ag to specific treatment be starteda(days)

3.3 ± 3.1

Number of positive CMV-Ag nuclei after specific treatment

 With Ganciclovirb

15 (1–500)

 No ganciclovirb

7 (1–4)

Co-Infectionsa

16 (72.7%)

Polymicrobial Infections

5 (22.7%)

CMV reactivation during hospitalization

0

Prophylaxis after standard Ganciclovir treatment

0

  1. aMean ± standard deviation; bMedian (minimum and maximum); AIRD Autoimmune Rheumatic Diseases, CMV-Ag cytomegalovirus antigenemia, SLE Systemic Lupus Erythematosus, RA Rheumatoid Arthritis